Corporate Profile

Cortexyme is a biopharmaceutical company developing therapeutics based on data supporting a new theory of the cause of Alzheimer's and other degenerative disorders. Cortexyme is targeting a specific pathogen tied to neurodegeneration. The target has been validated in a number of animal models and Cortexyme is enrolling patients in a Phase 2/3 clinical trial of its lead small molecule in mild to moderate Alzheimer's disease.

Stock Information

Copyright West LLC. Minimum 15 minutes delayed.

Investor Relations

News Releases

10 Feb '20
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Feb. 10, 2020-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat Alzheimer’s and other degenerative diseases, today announced that it has closed its private

Featured Reports

More information is coming soon.